References

1. Neet K, Hunter T. Vertebrate non-receptor protein tyrosine kinase families. Genes Cells 1996; 1:147-169.

2. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996; 1287:121-149.

3. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513-609.

4. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994; 8:23-32.

5. Biscardi JS, Tice DA, Parsons SJ. c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 1999; 76:61-119.

6. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem 2003; 278:1671-1679.

7. Li Y, Tondravi M, Liu J, et al. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001; 61:6906-6911.

8. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002; 94:344-351.

9. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-onco-gene leads to osteopetrosis in mice. Cell 1991; 64:693-702.

10. Duong LK, Lakkakorpi PT, Nakamura I, Machwate M, Nagy RM, Rodan GA. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J Clin Invest 1998; 102:881892.

11. Jeschke M, Brandi ML, Susa M. Expression of Src family kinases and their putative substrates in the human preosteoclastic cell line FLG 29.1. J Bone Miner Res 1998; 13:1880-1889.

12. Susa M, Missbach M, Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci 2000; 21:489-495.

13. Susa M, Teti A. Tyrosine kinase Src inhibitors: potential therapeutic applications. Drug News Perspect 2000; 13:169-175.

14. Altmann E, Widler L, Missbach M. N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src. Med Chem 2002; 2:201-208.

15. Metcalf CA III, van Schrevendijk MR, Dalgarno DC, Sawyer TK. Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Des 2002; 8:2049-2075.

16. Blake RA, Broome MA, Liu X, et al. SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000; 20:9018-9027.

17. Shakespeare WC. Src tyrosine kinase inhibitors for bone diseases. Abstracts of Papers, 223rd American Chemical Society National Meeting, April 7-11, 2002, Orlando.

18. Missbach M, Jeschke J, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24:437-449.

19. Recchia I, Rucci N, Funari A, et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]- pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK 1/2 pathway. Bone 2004; 34:65-79.

20. Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002; 277:12710-12717.

21. Recchia I, Rucci N, Festuccia C, et al. Pyrrolopyrimidine c-Src inhibitors reduce prostate cancer cell activity in vitro. Eur J Cancer 2003; 39:1927-1935.

22. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4:915-924.

23. He H, Hirokawa Y, Manser E, Lim L, Levitzki A, Maruta H. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J 2001; 7:191-202.

24. Susa M, Luong-Nguyen N-H, Crespo J, Maier R, Missbach M, McMaster G. Active recombinant human tyrosine kinase c-Yes: expression in baculovirus system, purification, comparison to c-Src, and inhibition by a c-Src inhibitor. Protein Expr Purif 2000; 19:99-106.

25. Menke A, Philippi C, Vogelmann R, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 2001; 61:3508-3517.

26. Su W, Sin M, Darrow A, Sherman L. Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberant CD44 expression. Glia 2003; 42:350-358.

27. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101:690-698.

28. Warmuth M, Simon N, Mitina O, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101:664-672.

29. Li S, Hu Y. Src kinase inhibitor CGP 76030 synergizes with STI571 in the treatment of B-cell acute lymphoblastic leukemia induced by the BCR/ABL oncogene in mice. The American Society of Hematology, 45th Annual Meeting, December 6-9, 2002, San Diego, California.

30. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63:375-381.

31. Paul R, Zhang ZG, Eliceiri BP, et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 2001; 7:222-227.

32. Fairchild R, Azimzadeh A, Pierson R, Miller G. Activation of Src family members in allografts. American Transplant Congress, April 26-May 1, 2002, Washington, DC.

33. Fowler T, Johansson S, Wary KK, Hook M. Src kinase has a central role in in vitro cellular internalization of Staphylococcus aureus. Cell Microbiol 2003; 5:417-426.

34. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-1934.

35. Gibson TJ, Spring J. Genetic redundancy in vertebrates: polyploidy and persistence of genes encoding multidomain proteins. Trends Genet 1998; 14:46-49.

36. Lakkakorpi PT, Nakamura I, Nagy RM, Parsons TJ, Rodan GA, Duong LT. Stable association of PYK2 and p130(Cas) in osteoclasts and their co-localization in the sealing zone. J Biol Chem 1999; 274:4900-4907.

37. Olayiole MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999; 274:17209-17218.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment